Polycystic Ovary Syndrome (PCOS) in Juvenile and Adult Type 1 Diabetes in a German/Austrian Cohort

Abstract

Context While an association between PCOS and type 2 diabetes is well established, to date there have been few data on clinical care of type 1 diabetes (T1D) patients with PCOS.

Objective The aim of our study was to characterize T1D patients with the comorbidity of PCOS within the DPV cohort with regard to diabetes phenotype, therapy and metabolic control.

Design and Setting Clinical data from the prospective German/Austrian DPV cohort on patients with T1D and documented PCOS (n=76) were compared to female T1D controls (n=32,566) in reproductive age.

Results The age at T1D manifestation in PCOS patients was later than in the control group (14.9±8.2 vs. 11.8±7.0 years, p<0.001). PCOS patients had higher BMI-SDS (0.92±0.11 vs. 0.38±0.01, p<0.001), metformin and oral contraceptives were used more frequently (p<0.001). A1c levels were significantly lower (7.92 +/− 0.23% vs. 8.43±0.01%, p<0.05) despite of lower insulin requirements (0.76±0.04 IU/kg/d vs. 0.84±0.00 IU/kg/d, p<0.05). In the PCOS group, higher rates of dyslipidemia (63.4 vs. 48.7%, p =0.032) and thyroid disorders (42.2% vs. 21.2%, p<0.001) were present.

Discussion While patients with T1D and comorbid PCOS showed features of a “type 1.5 diabetes” phenotype, insulin requirements per kg body weight were not higher and metabolic control was better, which could be explained only partially by additional metformin therapy. A more precise genetic and metabolic characterisation of these patients is needed to answer open questions on the underlying autoimmune process and residual ß-cell function.

• References

• 1 Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41
• 2 Asunción M, Calvo RM, San Millán JL. et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438
• 3 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
• 4 Legro RS, Arslanian SA, Ehrmann DA. et al. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-4592
• 5 Zawadsky J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR. ed. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992: 377-384
• 6 Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141-154
• 7 Salley KE, Wickham EP, Cheang KI. et al. Glucose intolerance in polycystic ovary syndrome–a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92: 4546-4556
• 8 Escobar-Morreale HF, Roldán-Martín MB. Type 1 diabetes and polycystic ovary syndrome: Systematic review and meta-analysis. Diabetes Care 2016; 39: 639-648
• 9 Rosario AS, Kurth B-M, Stolzenberg H. et al. Body mass index percentiles for children and adolescents in Germany based on a nationally representative sample (KiGGS 2003–2006). Eur J Clin Nutrition 2010; 64: 341-349
• 10 Hemmelmann C, Brose S, Vens M. et al. Percentiles of body mass index of 18 – 80-year-old German adults based on data from the Second National Nutrition Survey. Dtsch med Wochenschr 2010; 135: 848-852
• 11 Gerstl EM, Rabl W, Rosenbauer J. et al. Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27.035 patients from 207 centers in Germany and Austria during the last decade. Eur J Pediatr 2008; 167: 447-453
• 12 Knerr I, Wolf J, Reinehr T. et al. The ‘accelerator hypothesis’: relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. Diabetologia 2005; 48: 2501-2504
• 13 Gale EA. To boldly go-or to go too boldly? The accelerator hypothesis revisited. Diabetologia 2007; 50: 1571-1575
• 14 Codner E, Soto N, Lopez P. et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 2250-2256
• 15 Escobar-Morreale HF, Roldán B, Barrio R. et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4182-4187
• 16 Veldhuis JD, Klase PA, Sandow BA. et al. Progesterone secretion by highly differentiated human granulosa cells isolated from preovulatory Graafian follicles induced by exogenous gonadotropins and human chorionic gonadotropin. J Clin Endocrinol Metab 1983; 57: 87-93
• 17 Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988; 123: 733-739
• 18 Fröhlich-Reiterer EE, Rosenbauer J, Bechtold-Dalla Pozza S. et al. Predictors of increasing BMI during the course of diabetes in children and adolescents with type 1 diabetes: data from the German/Austrian DPV multicentre survey. Arch Dis Child 2014; 99: 738-743
• 19 Pozzilli P, Guglielmi C, Caprio S. et al. Obesity, autoimmunity, and double diabetes in youth. Diabetes Care 2011; 34: S166-S170
• 20 Cleland SJ, Fisher BM, Colhoun HM. et al. Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?. Diabetologia 2013; 56: 1462-1470
• 21 Park KH, Kim JY, Ahn CW. et al. Polycystic ovarian syndrome (PCOS) and insulin resistance. Int J Gynaecol Obstet 2001; 74: 261-267
• 22 Vella S, Buetow L, Royle P. et al. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010; 53: 809-820
• 23 Konrad K, Datz N, Engelsberger I. et al. Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria. Pediatr Diabetes 2015; 16: 529-537
• 24 Libman IM, Miller KM, DiMeglio LA. et al. for the T1D Exchange Clinic Network Metformin RCT Study Group Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes – a randomized clinical trial. JAMA 2015; 314: 2241-2250
• 25 Naderpoor N, Shorakae S, de Courten B. et al Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update 2015; 21: 560-574
• 26 Palomba S, Orio Jr F, Falbo A. et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 4068-4074
• 27 Balen AH, Morley LC, Misso M. et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 2016; 22: 687-708
• 28 Novais Jde S, Benetti-Pinto CL, Garmes HM. et al. Polycystic ovary syndrome and chronic autoimmune thyroiditis. Gynecol Endocrinol 2015; 31: 48-51
• 29 McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic Ovary Syndrome. N Engl J Med 2016; 375: 54-64
• 30 Goodman NF, Cobin RH, Futterweit W. et al. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome. Part 2. Endocr Pract 2015; 21: 1415-1426